(最終更新日:2024-06-14 15:58:45)
  ホッタ マサアキ   HOTTA MASAAKI
  堀田 雅章
   所属   関西医科大学  内科学第一講座
   職種   診療講師
■ 学術雑誌掲載論文
1. 原著(症例報告除く)  Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study 2024/03
2. その他  【新リンパ腫学-基礎・臨床の最新動向-】悪性リンパ腫診療に求められる疾患背景因子の基礎知識 医原性免疫不全に関連するリンパ増殖症 2023/03
3. 原著(症例報告除く)  Real-world efficacy of letermovir prophylaxis for cytomegaloviru infections after allogeneic hematopoietic stem cell transplantations: A single-center retrospective analysis 2022/09
4. 原著(症例報告除く)  Elevation of Early Plasma Biomarkers in Patients with Clinical Risk Factors Predicts Increased Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation 2021/08
5. 原著(症例報告除く)  Multiple Myeloma with Central Nervous System Relapse Early after Autologous Stem Cell Transplantation: A Case Report and Literature Review 2021
全件表示(45件)
■ 学会発表
1. Efficacy and Safety of Polatuzumab-Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Diffuse Large B-Cell Lymphoma in the Real-World Setting: A Single Institute Retrospective Study (ポスター掲示,一般) 2023/12/10
2. EGcacy and Safety of Polatuzumab-Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Diffuse Large B-Cell Lymphoma in the Real-World Setting: A Single Institute Retrospective Study (ポスター掲示,一般) 2023/12/10
3. The EIcacy and Safety of Polatuzumab- Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Diffuse Large B-Cell Lymphoma in the Real-World Setting: A Single Institute Retrospective Study (ポスター掲示,一般) 2023/12/10
4. 実臨床におけるベネトクラクス+アザシチジン療法の治療効果の検討 (口頭,一般) 2023/10/15
5. 臨床におけるベネトクラクス+アザシチジン療法の治療効果の検討 (口頭,一般) 2023/10/15
全件表示(79件)